Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems

Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treatment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. E. Matyunova, L. V. Bregel
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2017
Materias:	juvenile idiopathic arthritis genetically engineered biological drugs adverse events Science Q
Acceso en línea:	https://doaj.org/article/b58c11e40cd94dd5a015953c76545188
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b58c11e40cd94dd5a015953c76545188
record_format	dspace
spelling	oai:doaj.org-article:b58c11e40cd94dd5a015953c765451882021-11-23T06:14:38ZPresent day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems2541-94202587-959610.12737/article_5a3a0e4744a0a8.88140750https://doaj.org/article/b58c11e40cd94dd5a015953c765451882017-09-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/516https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treatment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive destruction of joints. However, the risk of adverse reactions against the background of this type of therapy requires further study. Aims: to analyze the efficiency of the genetically engineered drugs applied at juvenile arthritis and undesirable effects of this treatment. Materials and methods. Long-term (7 years) observations of 141 patients aged from 8 months to 18 with juvenile idiopathic arthritis. Results. The article summarizes the experience of successful application of genetically engineered biological preparations (tocilizumab, abatacept, etanercept, adalimumab) in 33 patients out of 141 patients with juvenile arthritis observed in Irkutsk. Serious infections were not registered, but we detected cases of managed neutropenia in 2 out of 12 patients receiving tocilizumab. In one case (3 %) out of 33 patients receiving genetically engineered drugs, the drug was withdrawn because of the risk of tuberculosis. Rare cases of secondary inefficiency of such drugs as abatacept, etanercept, adalimumab have been revealed. The tactics of treating children with undesirable reactions to genetically engineered drugs is described. Conclusions. Genetic engineering therapy has shown a good effect in improving clinical and functional indices and stopping joint destructive damage. However, when using genetically engineered drugs in treatment, the safety issues should be evaluated. Nevertheless, in our study there were no serious adverse events.A. E. MatyunovaL. V. BregelScientific Сentre for Family Health and Human Reproduction Problemsarticlejuvenile idiopathic arthritisgenetically engineered biological drugsadverse eventsScienceQRUActa Biomedica Scientifica, Vol 2, Iss 5(2), Pp 102-106 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	juvenile idiopathic arthritis genetically engineered biological drugs adverse events Science Q
spellingShingle	juvenile idiopathic arthritis genetically engineered biological drugs adverse events Science Q A. E. Matyunova L. V. Bregel Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
description	Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treatment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive destruction of joints. However, the risk of adverse reactions against the background of this type of therapy requires further study. Aims: to analyze the efficiency of the genetically engineered drugs applied at juvenile arthritis and undesirable effects of this treatment. Materials and methods. Long-term (7 years) observations of 141 patients aged from 8 months to 18 with juvenile idiopathic arthritis. Results. The article summarizes the experience of successful application of genetically engineered biological preparations (tocilizumab, abatacept, etanercept, adalimumab) in 33 patients out of 141 patients with juvenile arthritis observed in Irkutsk. Serious infections were not registered, but we detected cases of managed neutropenia in 2 out of 12 patients receiving tocilizumab. In one case (3 %) out of 33 patients receiving genetically engineered drugs, the drug was withdrawn because of the risk of tuberculosis. Rare cases of secondary inefficiency of such drugs as abatacept, etanercept, adalimumab have been revealed. The tactics of treating children with undesirable reactions to genetically engineered drugs is described. Conclusions. Genetic engineering therapy has shown a good effect in improving clinical and functional indices and stopping joint destructive damage. However, when using genetically engineered drugs in treatment, the safety issues should be evaluated. Nevertheless, in our study there were no serious adverse events.
format	article
author	A. E. Matyunova L. V. Bregel
author_facet	A. E. Matyunova L. V. Bregel
author_sort	A. E. Matyunova
title	Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
title_short	Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
title_full	Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
title_fullStr	Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
title_full_unstemmed	Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
title_sort	present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2017
url	https://doaj.org/article/b58c11e40cd94dd5a015953c76545188
work_keys_str_mv	AT aematyunova presentdaytherapyofjuvenileidiopathicarthritiswiththeuseofgeneticallyengineeredmedicinesinathirdlevelregionalhospitalresultsandproblems AT lvbregel presentdaytherapyofjuvenileidiopathicarthritiswiththeuseofgeneticallyengineeredmedicinesinathirdlevelregionalhospitalresultsandproblems
_version_	1718417029000593408

Present day therapy of juvenile idiopathic arthritis with the use of genetically engineered medicines in a third level regional hospital - results and problems

Ejemplares similares